Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Cocrystal Pharma, Inc.

Get SEC filing alerts via email and in your feed for Cocrystal Pharma, Inc.

COCP

Cocrystal Pharma, Inc.

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a biotechnology company focused on discovering and developing antiviral therapeutics targeting RNA viruses such as influenza, coronaviruses, norovirus, and hepatitis C. Utilizing proprietary structure-based drug design, it aims to create safe, effective, broad-spectrum, and resistance-high barrier antiviral drugs. Its core activities include preclinical and clinical research, with a focus on unmet medical needs in infectious diseases. The company relies on collaborations, third-party manufacturing, and advanced scientific platforms to develop innovative antiviral treatments.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Cocrystal Pharma, Inc.

1
1
Cocrystal Pharma, Inc. Cocrystal Pharma Reports Q1 2026 Financial Results with $2.3M Net Loss

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
Cocrystal Pharma, Inc. Cocrystal Pharma Reports $8.8 Million Net Loss for Fiscal Year 2025, Focuses on Antiviral Therapeutics

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Cocrystal Pharma, Inc. Cocrystal Pharma Reports $6.4 Million Net Loss for Nine Months Ended September 30, 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Cocrystal Pharma, Inc. Cocrystal Pharma Reports $2.1 Million Net Loss in Q2 2025, Significant Reduction in Operating Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Cocrystal Pharma, Inc. Cocrystal Pharma Reports $2.3 Million Net Loss in Q1 2025, Sees Improvement Year-Over-Year

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Cocrystal Pharma, Inc. Cocrystal Pharma Reports $17.5 Million Net Loss and Declining Cash Position for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Cocrystal Pharma, Inc. Cocrystal Pharma Reports Net Loss of $14.2M, Declines in Cash Position in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments